News Author: Laura Nikolaides Publish date: September 13, 2018
The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report, detailing recent advances in the fight against can...
News Author: Laura Nikolaides Publish date: September 12, 2018
The AACR annual Cancer Progress Report highlights 22 new approvals, including “revolutionary” CAR T-cell therapies, but maintains that increasing b...
News Author: Laura Nikolaides Publish date: August 20, 2018
The checkpoint inhibitor is approved with pemetrexed and platinum chemotherapy for first-line treatment of metastatic nonsquamous NSCLC, with no EG...
News Author: Laura Nikolaides Publish date: August 20, 2018
The checkpoint inhibitor is approved for patients with advanced SCLC whose cancer has progressed after platinum-based chemotherapy and at least one...
News Author: Laura Nikolaides Publish date: August 20, 2018
PI now requires separate companion diagnostics to determine PD-L1 levels in tumor tissue before use of pembrolizumab or atezolizumab as monotherapy...
News Author: Laura Nikolaides Publish date: August 16, 2018
Lenvatinib was found noninferior but not statistically superior to sorafenib for overall survival in a trial of 954 patients.
News Author: Laura Nikolaides Publish date: August 15, 2018
The trial will enroll 12-15 adult patients with non-Hodgkin lymphoma who have not responded to standard therapies.
News Author: Laura Nikolaides Publish date: August 9, 2018
ASCO and Friends of Cancer Research submitted recommendations for expanding clinical trial eligibility to the FDA, including lowering eligibility a...
News Author: Laura Nikolaides Publish date: July 18, 2018
Approval of the CDK 4/6 inhibitor was expanded to include the treatment of pre/perimenopausal women with HR-positive, HER2-negative, in combination...
News Author: Laura Nikolaides Publish date: June 5, 2018
The biosimilar decreases the chance of infection in patients with nonmyeloid cancer who are at risk of febrile neutropenia because of myelosuppress...
Video Author: Laura Nikolaides Publish date: June 5, 2018
CHICAGO – TAILORx is a “big win,” while SANDPIPER results are nothing to get excited about.
News Author: Laura Nikolaides Publish date: April 26, 2018
Incidence expected to be over 3,000 cases/year in United States by 2025.
News Author: Laura Nikolaides Publish date: April 23, 2018
A second interim analysis of the trial comparing Rocapuldencel-T in combination with sunitinib to sunitinib monotherapy led Argos Therapeutics to c...
News Author: Laura Nikolaides Publish date: April 19, 2018
Approval was based on a median PFS of 18.9 months for patients treated with osimertinib vs. 10.2 months for patients treated with standard-of-care ...
News Author: Laura Nikolaides Publish date: April 17, 2018
Approvals were granted for nivolumab and ipilimumab in combination for the treatment of intermediate- or poor-risk, previously untreated advanced r...
